ALLO EBITDA | Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (ALLO) EBITDA

2026-06-30: Basis Reported; EBITDA -$44.27M*; Operating income -$46.92M; Depreciation and amortization $2.65M*.
2026-03-31: Basis Reported; EBITDA -$43.22M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$39.35M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$41.80M*; Operating income -$44.90M; Depreciation and amortization $3.10M*.

Complete source-backed ebitda history.

Available history: 2018-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$44.27M*	-$46.92M	$2.65M*	$4.64M	-954.20%*	$150.00K*	-$32.00M*	(m)	$30.72M	(m)	(m)
2026-03-31	Reported	-$43.22M	(m)	(m)	(m)	(m)	$9.00K	-$12.91M	(m)	$32.00M	(m)	(m)
2025-12-31	Reported	-$39.35M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$41.80M*	-$44.90M	$3.10M*	$0.00	(m)	$243.00K*	-$29.69M*	(m)	$31.16M	(m)	(m)
2025-06-30	Reported	-$53.71M*	-$56.82M	$3.11M*	$0.00	(m)	$44.00K*	-$39.03M*	(m)	$40.16M	(m)	(m)
2025-03-31	Reported	-$62.09M	(m)	(m)	(m)	(m)	$99.00K	-$52.93M	(m)	$50.20M	(m)	(m)
2024-12-31	Reported	-$57.26M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$68.57M*	-$71.77M	$3.21M*	$0.00	(m)	$429.00K*	-$44.12M*	(m)	$44.71M	(m)	(m)
2024-06-30	Reported	-$67.79M*	-$71.43M	$3.64M*	$0.00	(m)	$0.00*	-$63.59M*	(m)	$50.35M	(m)	(m)
2024-03-31	Reported	-$65.95M	(m)	(m)	(m)	-299768.18%	$8.00K	-$55.90M	(m)	$52.26M	(m)	(m)
2023-12-31	Reported	-$81.63M	(m)	(m)	(m)	-388723.81%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$59.42M*	-$63.00M	$3.57M*	$22.00K	-270109.09%*	$12.00K*	-$55.53M*	(m)	$45.98M	(m)	(m)
2023-06-30	Reported	(m)	-$80.54M	(m)	$22.00K	(m)	$288.00K*	-$61.86M*	(m)	$62.04M	(m)	(m)
2023-03-31	Reported	(m)	-$99.09M	(m)	$30.00K	(m)	$1.03M	-$66.64M	(m)	$80.24M	(m)	(m)
2022-09-30	Reported	(m)	-$82.51M	(m)	$27.00K	(m)	$223.00K*	-$47.66M*	(m)	$63.64M	(m)	(m)
2022-06-30	Reported	(m)	-$76.62M	(m)	$64.00K	(m)	$1.37M*	-$42.53M*	(m)	$57.17M	(m)	(m)
2022-03-31	Reported	(m)	-$80.01M	(m)	$39.00K	(m)	$1.90M	-$68.24M	(m)	$60.16M	(m)	(m)
2021-09-30	Reported	(m)	-$77.67M	(m)	$49.00K	(m)	$3.35M*	-$48.88M*	(m)	$58.72M	(m)	(m)
2021-06-30	Reported	(m)	-$71.03M	(m)	$44.00K	(m)	$10.90M*	-$41.17M*	(m)	$52.29M	(m)	(m)
2021-03-31	Reported	(m)	-$33.20M	(m)	$38.34M	(m)	$6.46M	-$49.33M	(m)	$55.18M	(m)	(m)
2020-09-30	Reported	(m)	-$68.04M	(m)	$0.00	(m)	$20.25M*	-$37.59M*	(m)	$51.42M	(m)	$0.00
2020-06-30	Reported	(m)	-$63.16M	(m)	$0.00	(m)	$16.05M*	-$26.72M*	(m)	$47.30M	(m)	$0.00
2020-03-31	Reported	(m)	-$57.68M	(m)	$0.00	(m)	$12.25M	-$40.81M	(m)	$42.04M	(m)	$0.00
2019-12-31	Reported	(m)	-$64.58M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	(m)	-$55.01M	(m)	(m)	(m)	$18.40M*	-$31.93M*	(m)	$39.99M	(m)	$33.00K
2019-06-30	Reported	(m)	-$45.96M	(m)	(m)	(m)	$7.86M*	-$24.89M*	(m)	$31.77M	(m)	-$159.00K
2019-03-31	Reported	(m)	-$36.46M	(m)	(m)	(m)	$10.42M	-$30.26M	(m)	$23.40M	(m)	-$50.00K
2018-12-31	Reported	(m)	-$33.05M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	(m)	-$22.19M	(m)	(m)	(m)	$1.38M*	-$17.13M*	(m)	$10.87M	(m)	$0.00
2018-06-30	Reported	(m)	-$135.01M	(m)	(m)	(m)	$536.00K*	-$6.05M*	(m)	$122.49M	(m)	$0.00
2018-03-31	Reported	(m)	-$2.60M	(m)	(m)	(m)	$0.00	$5.00K	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$196.96M	(m)	(m)	(m)	(m)	$386.00K	-$149.25M	(m)	$150.15M	(m)	$0.00
2024-12-31	Reported	-$259.56M	(m)	(m)	(m)	-1179818.18%	$694.00K	-$200.30M	(m)	$192.30M	(m)	$443.00K
2023-12-31	Reported	-$313.54M	(m)	(m)	(m)	-330040.00%	$1.52M	-$237.73M	(m)	$242.91M	(m)	$0.00
2022-12-31	Reported	-$321.24M	(m)	(m)	(m)	-205920.51%	$5.19M	-$220.52M	(m)	$256.39M	(m)	$0.00
2021-12-31	Reported	-$169.69M	(m)	(m)	(m)	-148.74%	$21.45M	-$184.81M	(m)	$220.18M	(m)	$0.00
2020-12-31	Reported	-$250.84M	(m)	(m)	(m)	(m)	$65.96M	-$115.09M	(m)	$192.99M	(m)	$0.00
2020-09-30	Rolling	(m)	-$253.46M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$240.43M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$223.23M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$197.41M	(m)	(m)	(m)	(m)	$50.79M	-$137.35M	(m)	$144.53M	(m)	-$331.00K
2019-12-31	Rolling	(m)	-$202.01M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$170.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$137.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$226.71M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$191.84M	(m)	(m)	(m)	(m)	$3.23M	-$44.65M	(m)	$151.86M	(m)	-$117.00K
2018-12-31	Rolling	(m)	-$192.84M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Prime Medicine, Inc. (PRME)	United States	$0.557B	-3.54
Aura Biosciences, Inc. (AURA)	United States	$0.639B	-5.61
Autolus Therapeutics plc (AUTL)		$0.506B	-1.52
Entera Bio Ltd. (ENTX)		$0.485B
REGENXBIO Inc. (RGNX)	United States	$0.477B	-3.30
Tectonic Therapeutic, Inc. (TECX)	United States	$0.469B	-7.68
Eikon Therapeutics, Inc. (EIKN)	United States	$0.446B
Kyverna Therapeutics, Inc. (KYTX)	United States	$0.434B	-3.60
Editas Medicine, Inc. (EDIT)	United States	$0.424B	-4.29
4D Molecular Therapeutics, Inc. (FDMT)	United States	$0.733B	-4.10